We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
OptimizeRx Corp. (OPRX - Free Report) shares ended the last trading session 5.9% higher at $7.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.3% loss over the past four weeks.
The increase in share price can be attributed to the expanding market opportunity and a resilient business model. OPRX is witnessing increasing demand for the company’s innovative DAAP (Dynamic Audience Activation Platform) solution. The platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences across a strong network of clinical and personal platforms.
OPRX noted that its engagement with established clients remains strong while it is adding more new customers, especially in the mid-tier and long-tail life science companies. This is viewed by management as a highly attractive segment.
The company further addressed AI concerns, positioning it as a tailwind rather than a disruption risk, highlighting that AI is expected to free up marketing budgets, which usually are up to 50% allocated to content creation. These could be reallocated toward marketing execution and audience reach, areas where OptimizeRx excels, added management.
In addition to a fixed cost base and scalable operating model, EBITDA is gaining from cost discipline measures (post the Medicx buyout). OptimizeRx’s point-of-care (POC) and point-of-prescribe network and direct-to-consumer channels provide it a competitive edge.
Management has guided 2026 revenue to be between $109 million and $114 million and adjusted EBITDA in the band of $21–$25 million. The company also has a share repurchase plan of $10 million in place.
This company is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -75%. Revenues are expected to be $19.34 million, down 11.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For OptimizeRx, the consensus EPS estimate for the quarter has been revised 136.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on OPRX going forward to see if this recent jump can turn into more strength down the road.
OptimizeRx is a member of the Zacks Computer - Software industry. One other stock in the same industry, ACI Worldwide (ACIW - Free Report) , finished the last trading session 0.5% higher at $40.04. ACIW has returned 2% over the past month.
For ACI Worldwide, the consensus EPS estimate for the upcoming report has changed +52.6% over the past month to $0.45. This represents a change of -11.8% from what the company reported a year ago. ACI Worldwide currently has a Zacks Rank of #4 (Sell).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock?
OptimizeRx Corp. (OPRX - Free Report) shares ended the last trading session 5.9% higher at $7.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.3% loss over the past four weeks.
The increase in share price can be attributed to the expanding market opportunity and a resilient business model. OPRX is witnessing increasing demand for the company’s innovative DAAP (Dynamic Audience Activation Platform) solution. The platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences across a strong network of clinical and personal platforms.
OPRX noted that its engagement with established clients remains strong while it is adding more new customers, especially in the mid-tier and long-tail life science companies. This is viewed by management as a highly attractive segment.
The company further addressed AI concerns, positioning it as a tailwind rather than a disruption risk, highlighting that AI is expected to free up marketing budgets, which usually are up to 50% allocated to content creation. These could be reallocated toward marketing execution and audience reach, areas where OptimizeRx excels, added management.
In addition to a fixed cost base and scalable operating model, EBITDA is gaining from cost discipline measures (post the Medicx buyout).
OptimizeRx’s point-of-care (POC) and point-of-prescribe network and direct-to-consumer channels provide it a competitive edge.
Management has guided 2026 revenue to be between $109 million and $114 million and adjusted EBITDA in the band of $21–$25 million. The company also has a share repurchase plan of $10 million in place.
This company is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -75%. Revenues are expected to be $19.34 million, down 11.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For OptimizeRx, the consensus EPS estimate for the quarter has been revised 136.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on OPRX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
OptimizeRx is a member of the Zacks Computer - Software industry. One other stock in the same industry, ACI Worldwide (ACIW - Free Report) , finished the last trading session 0.5% higher at $40.04. ACIW has returned 2% over the past month.
For ACI Worldwide, the consensus EPS estimate for the upcoming report has changed +52.6% over the past month to $0.45. This represents a change of -11.8% from what the company reported a year ago. ACI Worldwide currently has a Zacks Rank of #4 (Sell).